Critical Analysis: Kadmon Holdings (KDMN) & Its Rivals

Kadmon Holdings (NASDAQ: KDMN) is one of 50 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Kadmon Holdings to related businesses based on the strength of its analyst recommendations, dividends, risk, earnings, institutional ownership, profitability and valuation.

Institutional & Insider Ownership

44.9% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Kadmon Holdings and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kadmon Holdings 1 1 3 0 2.40
Kadmon Holdings Competitors 128 791 1729 59 2.64

Kadmon Holdings currently has a consensus price target of $9.75, indicating a potential upside of 173.88%. As a group, “Biopharmaceuticals” companies have a potential upside of 12.37%. Given Kadmon Holdings’ higher possible upside, analysts clearly believe Kadmon Holdings is more favorable than its competitors.

Valuation and Earnings

This table compares Kadmon Holdings and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Kadmon Holdings N/A N/A -0.64
Kadmon Holdings Competitors $604.20 million $110.82 million 57.49

Kadmon Holdings’ competitors have higher revenue and earnings than Kadmon Holdings. Kadmon Holdings is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Kadmon Holdings and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kadmon Holdings -754.62% N/A -155.28%
Kadmon Holdings Competitors -12,963.17% -169.43% -23.50%


Kadmon Holdings competitors beat Kadmon Holdings on 7 of the 10 factors compared.

Kadmon Holdings Company Profile

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with's FREE daily email newsletter.

Leave a Reply